Bionomics and MSD Hosting Cognition and Alzheimer's Symposium Featuring Australian and US Speakers

ADELAIDE, Australia, Nov. 13, 2015 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will co-host a one-day symposium in Adelaide at the Crowne Plaza, Hindmarsh Square on Monday 16 November 2015 on Drug Discovery and Development for Cognition and Alzheimer's Disease featuring Australian and US experts.

Bionomics has combined with Merck & Co Inc., of Kenilworth NJ (known as Merck, Sharp and Dohme or MSD, outside the United States and Canada) to arrange the event.

This is the third annual Bionomics - MSD symposium and will be the biggest to date with over 200 registrations. Attendees include researchers, medical personnel and patient support groups as well as investors and life science analysts.

The purpose of the forum is to inform and discuss the latest advances in the understanding of these conditions and treatment options.

The symposium will be opened by Bionomics CEO and Managing Director Dr Deborah Rathjen and closed by Dr Susanne Fiedler MSD VP and Managing Director, Australia & New Zealand.

The keynote presentation will be by Dr Darryle Schoepp, Vice President & Therapeutic Area Head, Neuroscience, MSD on Challenges in Neuroscience Discovery and Development: What has Changed and Where are we Headed.

Dr Frank Yocca, Senior Vice President, CNS Research and Development of BioXcel will present Emerging Area for Drug Development: Psychiatric Based Symptoms of Neurodegenerative Disorders.

Another notable presenter is Dr Richard Hargreaves, Vice President, Discovery Science, Biogen who will speak on Use of Imaging for Neuroscience Drug Discovery and Development.

Please find the program here: http://bit.ly/1SniO5E
Registration is free.

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (alpha-7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

SOURCE Bionomics Limited

Related Links

http://www.bionomics.com.au